Tag: Cancer: Leukemia
Trametinib Safe, Effective for Juvenile Myelomonocytic Leukemia
Seven of 10 children with relapsed or refractory JMML completed all 12 cycles of therapy or used trametinib as bridge to HSCT
ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia
More patients receiving asciminib than investigator-selected tyrosine kinase inhibitor had major molecular response at 48 weeks
Oldest Adults With Acute Myeloid Leukemia Benefit From Venetoclax
Octogenarians and nonagenarians can be treated successfully with VEN-HMA
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
Six of 10 patients remained in minimal residual disease-negative complete remission after treatment
Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia
Those ending sFU had lower hospital visits per patient-year and longer time to first infection with no decrease in overall survival
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
Reduction in relapse incidence observed over time, as well as improvement in leukemia-free survival, overall survival
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
20 percent of patients treated with Breyanzi achieved a complete response
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
Overall survival inferior for acute myeloid leukemia patients with versus without central nervous system involvement
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
Risk for Cancer Increased for Relatives of Patients With Leukemia
Study finds increased risk for cancer overall and for specific cancers for first- and second-degree relatives
